Additionally, durable remission of coexisting conditions seen
WEDNESDAY, Nov. 6, 2024 (HealthDay News) — For teens undergoing bariatric surgery, weight loss and remission of coexisting conditions are durable after 10 years, according to a research letter published online in the Oct. 30 issue of the New England Journal of Medicine.
Justin R. Ryder, Ph.D., of the Ann and Robert H. Lurie Children’s Hospital of Chicago, and colleagues reported the 10-year outcomes for the Teen Longitudinal Assessment of Bariatric Surgery study. The analysis included 161 adolescents who underwent gastric bypass and 99 who underwent sleeve gastrectomy at a mean age of 17 years (83 percent followed to 10 years).
The researchers found that at 10 years, body mass index (BMI) decreased significantly (mean change, −20.0 percent), with similar changes between gastric bypass (mean change, −20.6 percent) and sleeve gastrectomy (mean change, −19.2 percent). Four distinct trajectories of changes in BMI over time were identified through a latent class analysis. Greater early weight loss (change in BMI at six months) was associated with a more favorable long-term BMI trajectory (odds ratio, 1.16). Remission of coexisting conditions at 10 years postsurgery was 55 percent for type 2 diabetes, 57 percent for hypertension, and 54 percent for dyslipidemia, indicating durable responses for most participants.
“These findings show the long-term durability of weight loss and remission of coexisting conditions after bariatric surgery, as well as the greater health benefits and durability of the effects in adolescents than would be expected in similarly treated adults,” the authors write.
Several authors disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Bariatric Surgery Is Effective Rescue Strategy After GLP-1 Receptor Agonist Failure
Weight-Loss Surgery Produces Lasting Diabetes Remission
2018 to 2025 Saw Sharp Rise in Postpartum GLP-1 Receptor Agonist Use
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Withdrawal From Medetomidine Increasingly Seen in ICUs
Study Looks at Patient Experiences With Sedative Contaminating Fentanyl
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists